4564.T Stock - OncoTherapy Science, Inc.
Unlock GoAI Insights for 4564.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $750.05M | $610.12M | $1.13B | $1.15B | $332.48M |
| Gross Profit | $-12,756,000 | $-177,718,000 | $41.69M | $113.91M | $19.54M |
| Gross Margin | -1.7% | -29.1% | 3.7% | 9.9% | 5.9% |
| Operating Income | $-797,936,000 | $-1,120,799,000 | $-1,106,415,000 | $-2,052,637,000 | $-1,637,936,000 |
| Net Income | $-815,285,000 | $-1,288,138,000 | $-1,118,644,000 | $-2,571,541,000 | $-1,561,636,000 |
| Net Margin | -108.7% | -211.1% | -98.6% | -222.9% | -469.7% |
| EPS | $-3.12 | $-6.05 | $-5.81 | $-13.72 | $-8.86 |
OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.
Visit WebsiteEarnings History & Surprises
4564.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | — | — | — | — |
Q4 2025 | Nov 7, 2025 | — | $-0.76 | — | — |
Q3 2025 | Aug 8, 2025 | — | $-1.13 | — | — |
Q2 2025 | May 8, 2025 | — | $-0.36 | — | — |
Q1 2025 | Feb 7, 2025 | — | $-0.63 | — | — |
Q4 2024 | Nov 8, 2024 | — | $-0.91 | — | — |
Q3 2024 | Aug 9, 2024 | — | $-1.30 | — | — |
Q2 2024 | May 10, 2024 | — | $-1.38 | — | — |
Q1 2024 | Feb 9, 2024 | — | $-1.27 | — | — |
Q4 2023 | Nov 10, 2023 | — | $-1.44 | — | — |
Q3 2023 | Aug 10, 2023 | — | $-1.99 | — | — |
Q2 2023 | May 12, 2023 | — | $-1.07 | — | — |
Q1 2023 | Feb 10, 2023 | — | $-1.55 | — | — |
Q4 2022 | Nov 4, 2022 | — | $-1.74 | — | — |
Q3 2022 | Aug 5, 2022 | — | $-1.44 | — | — |
Q2 2022 | May 6, 2022 | — | $-2.24 | — | — |
Q1 2022 | Feb 4, 2022 | — | $-4.73 | — | — |
Q4 2021 | Nov 5, 2021 | — | $-3.72 | — | — |
Q3 2021 | Aug 6, 2021 | — | $-3.00 | — | — |
Latest News
Frequently Asked Questions about 4564.T
What is 4564.T's current stock price?
What is the analyst price target for 4564.T?
What sector is OncoTherapy Science, Inc. in?
What is 4564.T's market cap?
Does 4564.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4564.T for comparison